Acuta Capital Partners LLC Purchases Shares of 44,000 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Acuta Capital Partners LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,000 shares of the company's stock, valued at approximately $680,000. Acuta Capital Partners LLC owned 0.18% of Artiva Biotherapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MetLife Investment Management LLC purchased a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $42,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $623,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock traded up $0.39 during midday trading on Thursday, reaching $12.60. The stock had a trading volume of 26,464 shares, compared to its average volume of 130,363. Artiva Biotherapeutics, Inc. has a 12 month low of $9.68 and a 12 month high of $17.31. The business has a 50-day moving average of $12.58.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current fiscal year.

Analysts Set New Price Targets

ARTV has been the subject of several analyst reports. Wedbush reiterated an "outperform" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price target on the stock. Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a "buy" rating and a $21.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Finally, TD Cowen began coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a "buy" rating for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $21.25.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.